Raltegravir
An antiretroviral medication belonging to the integrase inhibitor class, used as part of combination therapy to treat HIV infection by preventing the virus from inserting its genetic material into human cells. It is effective against HIV strains resistant to other drug classes.
Peso Molecular
444,4000 g/mol
LogP
1,10
TPSA
150,00 Ų
Regra dos 5 de Lipinski
Aprovado
Áreas Terapêuticas
Mecanismo de Ação
Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1
InChI
InChI=1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30)
Molecular Formula
C20H21FN6O5
HBD / HBA
3 / 9
Ligações Rotacionáveis
6
Átomos Pesados
32
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
An antiretroviral medication belonging to the integrase inhibitor class, used as part of combination therapy to treat HIV infection by preventing the virus from inserting its genetic material into human cells. It is effective against HIV strains resistant to other drug classes.
Inhibits viral integrase, preventing the insertion of viral DNA into the host cell genome and blocking viral replication.
Yes, Raltegravir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL254316. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 54671008. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="raltegravir"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/raltegravir/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/raltegravir/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/raltegravir/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="raltegravir"></drugfyi-drug>